Sei Investments Co. Takes $1.14 Million Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

Sei Investments Co. bought a new position in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 108,273 shares of the company's stock, valued at approximately $1,142,000. Sei Investments Co. owned about 0.11% of ARS Pharmaceuticals at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in SPRY. State Street Corp lifted its position in shares of ARS Pharmaceuticals by 10.4% in the third quarter. State Street Corp now owns 2,049,542 shares of the company's stock valued at $29,718,000 after buying an additional 193,321 shares during the last quarter. Geode Capital Management LLC lifted its holdings in ARS Pharmaceuticals by 3.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,234,805 shares of the company's stock valued at $17,909,000 after purchasing an additional 38,927 shares during the last quarter. Royce & Associates LP boosted its position in ARS Pharmaceuticals by 34.4% during the fourth quarter. Royce & Associates LP now owns 929,613 shares of the company's stock worth $9,807,000 after purchasing an additional 238,158 shares during the period. Raymond James Financial Inc. acquired a new position in shares of ARS Pharmaceuticals in the fourth quarter valued at $6,576,000. Finally, Levin Capital Strategies L.P. lifted its stake in shares of ARS Pharmaceuticals by 56.2% during the 4th quarter. Levin Capital Strategies L.P. now owns 467,627 shares of the company's stock worth $4,933,000 after buying an additional 168,201 shares during the last quarter. 68.16% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research analysts have weighed in on the stock. Oppenheimer assumed coverage on shares of ARS Pharmaceuticals in a report on Monday, February 10th. They issued an "outperform" rating and a $40.00 price target on the stock. William Blair reiterated an "outperform" rating on shares of ARS Pharmaceuticals in a research note on Monday, March 3rd. Scotiabank started coverage on ARS Pharmaceuticals in a research note on Friday, March 7th. They issued a "sector outperform" rating and a $30.00 price target for the company. Raymond James increased their price objective on ARS Pharmaceuticals from $26.00 to $28.00 and gave the stock a "strong-buy" rating in a research report on Tuesday, January 14th. Finally, Leerink Partners boosted their target price on shares of ARS Pharmaceuticals from $26.00 to $27.00 and gave the company an "outperform" rating in a research report on Monday, January 13th. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $31.00.

ARS Pharmaceuticals Price Performance

ARS Pharmaceuticals stock traded up $0.81 during mid-day trading on Friday, reaching $14.05. 2,203,480 shares of the company were exchanged, compared to its average volume of 1,138,938. The firm has a market cap of $1.38 billion, a PE ratio of -27.55 and a beta of 0.86. The company has a fifty day simple moving average of $12.00 and a 200-day simple moving average of $13.04. ARS Pharmaceuticals, Inc. has a 12 month low of $7.55 and a 12 month high of $18.51.

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last issued its quarterly earnings results on Thursday, March 20th. The company reported $0.52 EPS for the quarter, topping analysts' consensus estimates of ($0.04) by $0.56. The company had revenue of $86.58 million during the quarter, compared to the consensus estimate of $15.46 million. Sell-side analysts anticipate that ARS Pharmaceuticals, Inc. will post -0.55 earnings per share for the current year.

Insider Buying and Selling at ARS Pharmaceuticals

In other ARS Pharmaceuticals news, insider Eric Karas sold 10,000 shares of the company's stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $14.00, for a total transaction of $140,000.00. Following the completion of the sale, the insider now directly owns 7,696 shares in the company, valued at $107,744. This represents a 56.51 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Laura Shawver sold 49,600 shares of the business's stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $11.21, for a total value of $556,016.00. Following the transaction, the director now directly owns 210,346 shares of the company's stock, valued at $2,357,978.66. This trade represents a 19.08 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 159,602 shares of company stock valued at $1,926,541 in the last ninety days. 40.10% of the stock is currently owned by company insiders.

ARS Pharmaceuticals Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.